News

TCT: Absorb BVS meets pivotal U.S. noninferiority goal


 

AT TCT 2015

References

ABSORB III was sponsored by Abbott Vascular, which markets the Absorb BVS. Dr. Kereiakes has been a consultant to Abbott Vascular as well as to HCRI, Boston Scientific, Svelte, Janssen, and Sanofi-Aventis, and he holds equity interest in Ablative Solution. Dr. Stone has received grant support and consultant fees from Abbott Vascular and has been a consultant to 12 other companies and holds equity options in 8t companies. Dr. Simon has received research grants from and has been a consultant to Medtronic and a consultant to Cordis, Merck, and Janssen. Dr. Leon had no relevant disclosures.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Pages

Recommended Reading

Sunshine Act shows vascular surgeons reap more industry payments
MDedge Cardiology
Readmissions rise with endovascular lower limb procedures
MDedge Cardiology
‘Minimalist’ TAVR has short learning curve
MDedge Cardiology
Women dogged by unplanned readmissions after aortic surgery
MDedge Cardiology
Remote ischemic preconditioning does no good
MDedge Cardiology
Reattaching intercostals fails to squelch spinal cord ischemia in TAAA repairs
MDedge Cardiology
FDA approves first bioabsorbable-polymer stent
MDedge Cardiology
Endovascular treatment of acute IVC thrombosis found effective
MDedge Cardiology
TCT: Absorbable metal scaffold performs well in BIOSOLVE II
MDedge Cardiology
ESC: What’s the hottest recent advance in cardiology? And the winner is …
MDedge Cardiology

Related Articles